Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals
Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals
Recruiting · NCT06762730 · Registry updated 2025-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals | Bone Diseases, Metabolic, Nutritional and Metabolic Diseases, Osteopenia, bone disorder, metabolic disease, musculoskeletal system disorder | Recruiting | Phase 4 | 2025-09-18 | NCT06762730 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hadassah Medical Organization | 53 |
| Rambam Health Care Campus | 34 |
| Sheba Medical Center | 63 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hadassah Hebrew University Medical Center | Jerusalem | Israel | 2 |
| Rambam Medical Center | Haifa | Israel | 19 |
| Sheba Medical Center | Ramat Gan | Israel | 43 |